← Back to Clinical Trials
Recruiting NCT07713030

NCT07713030 Comparative Effects of High-Intensity Interval Training and Continuous Endurance Training Among Prediabetic Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07713030
Status Recruiting
Phase
Sponsor Riphah International University
Condition PreDiabetes
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2026-05-01
Primary Completion 2026-08-01

Eligibility & Interventions

Sex All sexes
Min Age 35 Years
Max Age 54 Years
Study Type INTERVENTIONAL
Interventions
High-Intensity Interval TrainingContinuous Endurance Training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 80 participants in total. It began in 2026-05-01 with a primary completion date of 2026-08-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Prediabetics is a condition where blood sugar levels are normal but not yet high enough to be diagnosed as type 2 diabetes. This phase offers a crucial point for timely intervention to delay or prevent type 2 diabetes. The objective of the study will be to find the effects of high intensity interval and continuous endurance training on glycemic control, BMI, Vo2 Max, pulmonary function and physical activity among prediabetic patients. Study design will be randomized control trial. Total 80 participants will be enrolled in study. The data will be collected from faculty of Riphah International University, Lahore. The study will be completed within 8 months after approval of synopsis. A simple random sampling will be used to assign the groups; group A and group B. Group A will be assigned high intensity interval training and group B will be assigned to continuous training.

Eligibility Criteria

Inclusion Criteria: * Sedentary lifestyle (Individuals reporting minimal structured physical activity e.g., \<30 minutes of exercise per week) . * Stable Medical Condition (No history of significant cardiovascular events, uncontrolled hypertension, or other major comorbidities). * Stable Body Weight (Stable body weight with changes less than 3 kg in the past 6 months). Exclusion Criteria: * uncontrolled hypertension * history of heart disease * myocardial infarction * stroke * Use of Specific Medications (Current use of insulin or other medications affecting glucose metabolism or exercise response) * Severe Obesity (Individuals with a BMI ≥ 40 kg/m) * High fasting blood glucose (Fasting blood glucose of \>100mg.dl-1) * Previous history of respiratory problems * Smoking

Contact & Investigator

Central Contact

Muhammad Iqbal Tariq, Phd

✉ iqbal.tariq@riphah.edu.pk

📞 333826752

Principal Investigator

Arjumand Bano, MS

PRINCIPAL INVESTIGATOR

Riphah International University

Frequently Asked Questions

Who can join the NCT07713030 clinical trial?

This trial is open to participants of all sexes, aged 35 Years or older, up to 54 Years, studying PreDiabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07713030 currently recruiting?

Yes, NCT07713030 is actively recruiting participants. Contact the research team at iqbal.tariq@riphah.edu.pk for enrollment information.

Where is the NCT07713030 trial being conducted?

This trial is being conducted at Lahore, Pakistan.

Who is sponsoring the NCT07713030 clinical trial?

NCT07713030 is sponsored by Riphah International University. The principal investigator is Arjumand Bano, MS at Riphah International University. The trial plans to enroll 80 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology